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Background: The activation of inflammatory cells and the production of matrix metalloproteinases (MMPs) are important
in the pathogenesis of abdominal aortic aneurysm (AAA). Previous studies have demonstrated that the antiplatelet agent
trapidil has multiple actions, including suppression of MMP expression through the inhibition of the CD40–CD40
ligand (CD40-CD40L) pathway in cultured cells. A recent clinical study suggested that trapidil might have functions
beyond its antiplatelet action.
Methods and results: In the present study, we performed immunohistochemical analysis and semiquantitative reverse
transcription–polymerase chain reaction to evaluate the effect of trapidil on the production of MMPs in cultured aortic
tissues from patients with infrarenal AAA (n 9) and control patients with aortoiliac occlusive disease (n 7). The tissue
concentrations of both MMP-2 and MMP-9 were significantly higher in AAA walls than in control aortic walls. Both
trapidil and an anti-CD154 (CD40L) antibody significantly suppressed the protein production and mRNA expression of
MMP-2 but did not inhibit those of MMP-9 in organ cultures of AAA wall specimens. MMP-9 was produced by
macrophages and a lot of neutrophils in AAA tissues, whereas MMP-2 was derived from macrophages. CD40 was
expressed on macrophages but not on neutrophils, and this expression could explain the differential effect of trapidil on
the production of MMP-2 and MMP-9.
Conclusions: Trapidil, a CD40-CD40L pathway inhibitor, suppressed mRNA expression and protein production of
MMP-2 in AAA tissues, suggesting a potential therapeutic approach for the prevention or treatment of AAA. (J Vasc
Surg 2004;39:447-53.)
Abdominal aortic aneurysm (AAA) is a potentially fatal
disorder that affects 2% to 9% of the population older than
65 years.1,2 Although elective surgical repair or endovascu-
lar stent grafting is effective in preventing death from
ruptured AAA, there is a conspicuous absence of alternative
noninvasive therapeutic strategies for this disease.3
Because human aortic aneurysms are characterized by
destructive remodeling of the aortic wall, investigations
have emphasized the mechanism underlying the degrada-
tion of matrix proteins in aneurysm wall.4,5 Several reports
have demonstrated that matrix metalloproteinases (MMPs)
contribute to the formation and progression of AAA.6-8
Particularly, MMP-2 and MMP-9 have been demonstrated
to be up-regulated in vascular smooth muscle cells from
patients with AAA,9,10 and MMP-9 has been reported to be
related to the size or natural history of AAA.11,12 A recent
study using MMP-2–deficient mice and MMP-9–deficient
mice showed that two MMPs, MMP-2 and MMP-9, work
in concert to produce AAA.13 These observations have led
to the speculation that MMP-2 and/or MMP-9 might be
essential for the development of AAA and, thus, might be a
possible key target for pharmacotherapy.14,15
An antiplatelet drug, trapidil, has been shown to have
numerous effects, and it suppresses the in vitro expression
of various inflammatory molecules, including MMPs by
way of the CD40–CD40 ligand (CD40-CD40L) path-
way.16,17 The CD40-CD40L pathway has been reported to
play a central role in the inflammatory aspect of atheroscle-
rotic plaque formation, progression, and subsequent rup-
ture by suppressing MMP activity.18,19 In fact, a multi-
center clinical trial in Japan has shown that trapidil might
have more beneficial effect than aspirin on cardiovascular
events after myocardial infarction.20
Therefore, we hypothesized that trapidil might have an
inhibitory effect on the production of MMP-2 and/or
MMP-9 in AAA tissues and might be a potential therapeu-
tic tool for this disease.14,15 To address this hypothesis, we
investigated the concentrations of MMP-2 and MMP-9 in
aortic tissues from patients with AAA and control patients,
assessed the effect of trapidil on the production of these
MMPs by organ cultures of AAA wall tissues, and performed
an immunohistochemical analysis of MMP-2 and MMP-9.
METHODS
Subjects. Nine male patients (aged 64.6  4.1 years)
with infrarenal AAA and 7 control male patients (aged 69.2
 5.4 years) with aortoiliac occlusive disease were enrolled
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in the present study at Tokyo Women’s Medical University
Hospital. Mean value of the maximum AAA diameter was
5.8 cm. None of the patients were given antiplatelet drugs
for at least 1 week before surgery. AAA specimens were
obtained from the central portion of the aneurysmal aorta
of patients with AAA, and control specimens were collected
from the proximal portion of the diseased aorta of patients
with aortoiliac occlusive disease during elective surgery.
After the specimens were harvested, portions of each were
immediately placed into phosphate-buffered saline (PBS;
pH 7.2) for organ culture, 4% paraformaldehyde for immu-
nohistochemical analysis, or stored in liquid nitrogen for
the preparation of protein and mRNA. This study was
approved by the human ethics committee of our institute,
and all subject patients gave written informed consent.
Organ culture of aortic wall specimens. Each spec-
imen was cut into several small pieces (approximately 0.5
cm3) and was incubated with culture medium for vascular
smooth muscle cells (VSMCs; HuMedia-SG2; Kurabou,
Osaka, Japan) containing various concentrations of trapidil
(1-100 mol/L) or vehicle in an atmosphere of 95%
O2/5% CO2 for 48 hours at 37°C, as described previous-
ly.15,21 Anti-CD154 (CD40L) blocking monoclonal anti-
body (10 mol/L, Sigma, St Louis, Mo) or aspirin (100
mol/L, Sigma) was also added to some of the cultures.
After 48 hours of culture, total RNA and total protein were
prepared from each sample.
Measurement of the tissue concentrations of
MMP-2, MMP-9, TIMP-1, and TIMP-2. The aortic
tissue levels of total MMP-2, MMP-9, tissue inhibitor of
metalloproteinase 1 (TIMP-1), and TIMP-2 were exam-
ined by enzyme immunoassay (EIA; Fuji Chemical Ltd,
Toyama, Japan) with the use of antibodies directed against
human MMP-2, human MMP-9, human TIMP-1, and
human TIMP-2. Active MMP-2 and active MMP-9 were
detected through detection enzyme and the subsequent
cleavage of its substrate with the use of the Biotrak MMP-2
activity assay system and the Biotrak MMP-9 activity assay
system (both from Amersham, Arlington Heights, Ill).
Reverse transcription–polymerase chain reaction.
Total RNA was isolated from aortic specimens using
TRIzol reagent (Gibco BRL, Grand Island, NY), and re-
verse transcription (RT) of an aliquot (5 g) of the total
RNA sample was done by using reverse transcriptase (Su-
perscript II; Gibco BRL). Then polymerase chain reaction
(PCR) of the complementary DNA to detect the human
MMP-2 and MMP-9 genes was performed by a pro-
grammed cycle of 94°C for 30 seconds (denaturation),
Fig 1. Trapidil significantly reduced the levels of active MMP-2 in a concentration-dependent manner in organ
cultures (A) but did not alter that of MMP-9 (B). Value of the trend test, P  .001.
Fig 2. Effect of trapidil (10 mol/L), anti-CD154 (100 mol/
L), or aspirin (10 mol/L) on active MMP-2 production in AAA
tissues. Both trapidil and anti-CD154 antibody inhibited MMP-2
production. *P  .01 vs lane 1.
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58°C for 30 seconds (annealing), and 72°C for 45 seconds
(polymerization). As an internal control, co-amplification
of glyceraldehyde phosphate dehydrogenase (GAPDH)
was performed. The sequences of the oligonucleotide
primers used and the expected size are shown in the Table.
The number of PCR cycles was 35, and products were
analyzed on agarose gels. To determine whether the PCR
was in the linear range, various amounts of total RNA were
used to amplify each gene. Semiquantification of mRNA
expression was achieved by densitometric analysis by using
National Institutes of Health (NIH) image analysis soft-
ware. This analysis confirmed the linear amplification of
RNA at amounts from 0.1 to 5.0 g (data not shown),
indicating that RT-PCR was performed within the linear
range in the present study.
Immunohistochemical assays. We used hematoxylin
and eosin staining to assess the overall tissue architecture.
Immunohistochemistry was performed with a labeled
streptavidin biotin (LSAB) kit (Dako, Glostrup, Denmark),
and mouse monoclonal antibodies were directed against
human T cells (human CD68; Dako), human macrophages
(human CD45RO; Dako), human neutrophils (human
neutrophil elastase; BD Pharmingen, San Diego, Calif),
human MMP-2 (Fuji Chemical Ltd), human MMP-9 (Fuji
Chemical Ltd), and human CD 40 (Santa Cruz, Santa
Cruz, Calif). The investigators who performed the histo-
logic evaluation were blinded to the clinical data.
Statistical analysis. Analyses were performed with
SAS System 8e software (SAS Institute Inc, Cary, NC).
Results are presented as the mean  SD. The normality of
the distribution of data was evaluated by the Shapiro-Wilks
one-sample test, and the F test was used to assess the
homogeneity of variance. The Student t test was used for
the comparison of continuous data. A simple linear regres-
sion model was used to perform the trend test. One-way
analysis of variance was used to test for significant differ-
ences between the groups, and Dunnett multiple compar-
ison method was applied when appropriate. A two-tailed
P  .05 was considered to indicate statistical
significance.
RESULTS
Production of MMP-2 and MMP-9. We investi-
gated the tissue concentrations of total and active MMP-2
and MMP-9 in AAA walls. Both total and active MMP-2
and MMP-9 showed significantly higher levels in the aortic
tissues from patients with AAA than in tissues from control
patients (data not shown), which is the same pattern as
previous studies have demonstrated.
Effect of trapidil on the production of MMP-2 and
MMP-9. We subsequently tested whether trapidil had an
influence on the protein level of MMP-2 or MMP-9 in AAA
tissues. Addition of trapidil (1-100 mol/L) to organ
cultures significantly reduced the tissue levels of MMP-2 in
a concentration-dependent manner, although it did not
alter the tissue concentration of MMP-9 (Fig 1). Suppres-
sion of MMP-2 by blocking the CD40-CD40L interaction
was also examined by using anti-CD154 antibody. This
antibody inhibited the production of MMP-2 (Fig 2), but
did not suppress MMP-9 production in cultured AAA walls
Fig 3. Representative pattern of semiquantitative RT-PCR for MMP-2 and MMP-9. Trapidil suppressed MMP-2
mRNA expression but not MMP-9 mRNA expression.
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Fig 4. Immunohistochemical analysis. A, Hematoxylin and eosin staining. AAA tissue contains numerous inflamma-
tory cells (magnification, 40). B, MMP-2 is positive on macrophages (magnification, 400). C and D, MMP-9 is
produced by macrophages, a lot of neutrophils circulating in blood vessels, or neutrophils infiltrating into the aortic wall
tissue (magnification, 400).
Fig 5. Immunostaining for CD40. A, Low magnification (40). B, High magnification (400). CD40 was expressed
on B cells, T cells, and macrophages. Neutrophils did not express CD40.
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(data not shown), indicating that the secretion of MMP-2
(but not MMP-9) was controlled by way of the CD40-
CD40L pathway in AAA tissues. Neither TIMP-1 produc-
tion nor TIMP-2 production was affected by trapidil (data
not shown).
Effect of trapidil on mRNA expression of MMP-2
and MMP-9. We examined the effect of trapidil on
mRNA expression of MMP-2 and MMP-9 in cultured AAA
wall tissues. Semiquantitative RT-PCR demonstrated that
trapidil treatment (10 mol/L) suppressed MMP-2
mRNA expression but not MMP-9 mRNA expression (Fig
3).
Immunohistochemical analysis. The walls of AAAs
contained many inflammatory cells, such as T cells, B cells,
macrophages, mast cells, and neutrophils. Staining for
MMP-2 was positive in the macrophages, whereas MMP-9
was positive in the macrophages and a lot of neutrophils
(Fig 4), indicating that these cells were the source of
MMP-2 and MMP-9 in AAA tissues. After the treatment of
trapidil, MMP-2–positive macrophages were not detected
(Fig 4), although MMP-9–positive neutrophils could be
demonstrated (data not shown). Smooth muscle cells have
also been reported to produce MMPs,9,10 but no smooth
muscle cells with positive staining for MMP-2 or MMP-9
were detected in AAA tissues examined in the present
study. Previous studies have focused on the interaction
between CD40 expressed by macrophages and CD40L
expressed by T cells in atherosclerotic lesions. In the
present examinations, CD40 was expressed mainly on T
cells, B cells, and macrophages but not on neutrophils (Fig
5). CD40-positive vascular smooth muscle cells were not
detected.
DISCUSSION
In atherosclerotic plaques, the importance of the acti-
vation of inflammatory cells and subsequent MMP secre-
tion has been emphasized for its instability.22,23 Aneurys-
mal degeneration of the aorta also involves destructive
remodeling of the aortic wall matrix that is associated with
chronic inflammation and local overproduction of
MMPs.4,5
The present study demonstrated two major findings.
First, the incubation with trapidil suppressed both the
mRNA expression and protein production of MMP-2 in
cultured AAA tissues. Previous studies have demonstrated
up-regulation of MMP-2 expression6 and MMP-2 activity9
in AAA. Although a relationship between serum MMP-2
level and the clinical course of patients with AAA has not
been determined, a recent study revealed the synergistic
role of MMP-2 and MMP-9 in experimental AAA forma-
tion in mice,13 indicating that MMP-2 might play a critical
role in the pathogenesis and development of AAA. Trapidil
is an antiplatelet agent. Recent studies have demonstrated
that trapidil not only has platelet-dependent effects but also
possesses platelet-independent effects mediated by way of
the CD40-CD40L pathway that involve modulating the
expression of various molecules, including MMPs, indicat-
ing a potential of trapidil for stabilizing arterial plaques.17
In fact, the possibility for the superiority of trapidil over
aspirin was demonstrated by a multicenter study in patients
after acute myocardial infarction,20 suggesting that trapidil
could exert actions beyond its antiplatelet effect clinically.
In vitro studies have revealed that doxycycline inhibits
activity of MMPs,24 and this drug has a clinical benefit
against AAA progression.25,26 Compared with doxycycline,
Fig 6. Schematic hypothesis for the inhibitory effect of trapidil on AAA formation and progression.
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trapidil does not have any evidence for AAA. However,
taking the present results together with an evidence for
coronary artery disease, trapidil would be useful, particu-
larly for patients with AAA with coronary artery disease.
Second, trapidil did not have a detectable inhibitory
effect on mRNA expression and protein production of
MMP-9 in AAA tissues, which differs from the effect on
MMP-2 production. Because anti-CD154 antibody also
inhibited MMP-2, but not MMP-9 (data not shown), this
difference was considered to be through the differential
effect on the CD40-CD40L pathway.16,17 In the AAA
wall, CD40 was expressed mainly on T cells, B cells, and
macrophages, but not on neutrophils, and previous studies
reported that T cells express CD40L in the arterial
wall.16-19 As we showed in the present study, the cellular
source of MMP-9 was macrophages and neutrophils
whereas MMP-2 was macrophage derived in our AAA
samples, although several reports have shown that neutro-
phils produce not only MMP-9 but also MMP-2. We,
therefore, postulated two possibilities for this difference in
the effect of trapidil on MMP-2 and MMP-9. One possi-
bility is that MMP-9 was derived from neutrophils to a
greater extent than from macrophages in our AAA samples
and that trapidil has fewer effects on neutrophils than on
macrophages because neutrophils do not express CD40.
Another possibility is that MMP-9 production in human
AAA is not dependent on the CD40-CD40L pathway,
whereas MMP-2 production is dependent. Further investi-
gations will be necessary to elucidate these possibilities (Fig
6).
The CD40-CD40L interaction is a critical step for the
initiation of immune response, and this pathway has been
reported to be involved in various inflammatory disorders,
including atherosclerotic diseases,18,19 indicating a poten-
tial of the CD40-CD40L inhibition therapy for these dis-
eases. Trapidil, a CD40-CD40L pathway inhibitor, is a
promising drug for atherosclerotic diseases such as coro-
nary artery disease and/or AAA as shown in the present
study. The maximal drug concentration after the adminis-
tration of clinical dose (100 mg) of trapidil is 16.1 M,
which is referred from the Japan Pharmaceutical Informa-
tion Center.17 The concentration of trapidil used in our
organ culture experiments was close to this level in humans,
indicating that the effect on AAA tissues shown in the
present ex vivo study might be reproduced in the clinical
setting.
Limitations. In the present study, mRNA expression
was evaluated by RT-PCR, and EIA was used to measure
MMP protein levels. We were unable to examine the enzy-
matic activity of MMPs by enzyme zymography because of
the limited size of the human samples obtained from pa-
tients. MMPs are secreted as a complex with TIMPs by
most cells, so it might be reasonable to expect that TIMP-1
or TIMP-2 could also be affected by trapidil. However, we
found that the TIMP-1 and TIMP-2 concentrations in
AAA tissues were not changed by incubation with trapidil
for 48 hours (data not shown). Although the present
analysis confirmed that neutrophils secrete MMP-9 in AAA
tissues, the contribution of neutrophils in vascular remod-
eling is controversial.27,28 Further investigations will be
necessary to elucidate the functional role of neutrophils in
the pathogenesis of AAA.
Conclusions. The present study demonstrated that
trapidil, a CD40-CD40L pathway inhibitor, can suppress
the mRNA expression and protein production of MMP-2
that contributes to elastolysis and remodeling of AAAs,
suggesting that trapidil might have a potential clinical value
for preventing or treating this disease.
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